All In Biotech

Drug Trial Radar · NCT06774313

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Jan 22, 2025

Primary completion

Apr 8, 2026

Study completion Apr 8, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-142Drug

    Intravenous (IV) Infusion

  • ABBV-142Drug

    Subcutaneous (SC) Injection

  • PlaceboDrug

    IV Infusion

  • PlaceboDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to Day 120
  2. Maximum Observed Serum Concentration (Cmax) of ABBV-142Time frame: Up to Day 120
  3. Time to Cmax (Tmax) of ABBV-142Time frame: Up to Day 120
  4. Area Under the Serum Concentration-time Curve (AUC) of ABBV-142 from Time 0 to the Time of Last Measurable Concentration (AUCt)Time frame: Up to Day 120
  5. AUC of ABBV-142 from Time 0 to Infinity (AUCinf)Time frame: Up to Day 120
  6. Terminal Phase Elimination Rate Constant (β) of ABBV-142Time frame: Up to Day 120
  7. Terminal Phase Elimination Half-life (t1/2) of ABBV-142Time frame: Up to Day 120
  8. Dose Normalized Cmax of ABBV-142Time frame: Up to Day 120
  9. Dose Normalized AUC of ABBV-142Time frame: Up to Day 120

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 271899

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.